Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot.
A total of 20 women with regular menstrual cycles normal ovulatory function were randomized to receive 3.75 mg or 1.87 mg of D-Trp-6-luteinizing hormone-releasing hormone (LHRH) in microcapsules either in the early follicular phase (day 2) or during the mid-luteal phase (day 21) of the menstrual cycle. Pituitary--ovarian function was studied by sequential plasma measurements of oestradiol, follicle stimulating hormone, luteinizing hormone and progesterone. Our results show that the full, standard dose (3.75 mg) of D-Trp-6-LHRH depot and the half-dose (1.87 mg) were equally effective in their desensitizing action, and that desensitization occurs more rapidly with early follicular phase administration of the analogue.
Balasch
J
J
Department of Obstetrics and Gynaecology, Faculty of Medicine, Hospital Clínic i Provincial, Barcelona, Spain.
Gómez
F
F
Casamitjana
R
R
Carmona
F
F
Rivera
F
F
Vanrell
J A
JA
D000328:Adult; D002214:Capsules; D015536:Down-Regulation; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000187:drug effects; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism; D010060:Ovulation / Q000187:drug effects; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000494:pharmacology*
D002214:Capsules; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone